Chiasma IPO

7/16/2015

IPO

$102,400,000

We intend to use the net proceeds from this offering as follows: approximately $32.0 million to build our corporate infrastructure, including our U.S. sales and marketing operations, to support the commercial launch of oral octreotide in the United States for the treatment of acromegaly; approximately $15.0 million to initiate an additional Phase 3 clinical trial of oral octreotide to support regulatory approval in Europe for the treatment of acromegaly; and approximately $3.0 million to initiate a Phase 2 clinical trial of oral octreotide for the treatment of neuroendocrine tumors. We expect to use the remainder of any net proceeds from this offering to initiate clinical trials of oral octreotide in a new orphan indication, once selected, in late 2016 and for research and development on our TPE platform to enable us to develop additional product candidates targeting new indications and announce at least one new product candidate for clinical development in late 2016, and for working c

Private & Independent

Biopharmaceutical

460 Totten Pond Rd. 530
Waltham, MA 02451
USA

Chiasma is focused on improving the lives of patients by developing and ultimately commercializing oral therapies that eliminate the significant limitations and burdens generally associated with therapies that are currently only available as injections.